Susana M. Campos, MD, MPH

The FRα-directed ADC rinatabart sesutecan showed disease control regardless of biomarker status and is now under investigation in the phase 3 RAINFOL-03 trial.

Starting lenvatinib at 14 mg instead of the trial’s 20-mg dose helps patients remain on therapy, according to Susana Campos, MD, MPH.

Because it is not biomarker directed, lenvatinib plus pembrolizumab remains broadly useful even as HER2-targeted ADCs enter recurrent uterine cancer.

The platinum-free interval is prognostic but not predictive for lenvatinib plus pembrolizumab, Susana Campos, MD, MPH, told CancerNetwork.

Five-year follow-up showed 37% overall survival rate with lenvatinib plus pembrolizumab in dMMR endometrial cancer.

Up to 55% of endometrial tumors show HER2/neu heterogeneity, explained Susana Campos, MD, MPH, making biopsy at recurrence key for ADC eligibility.

A retrospective series found a 75% response rate adding lenvatinib after pembrolizumab progression in dMMR endometrial cancer, said Susana Campos, MD, MPH.